Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30105% above fair value
$3.99−0.07 (-1.72%)
Close on Nov 13, 2026Market cap $1.40BP/E –Yield –
Nuvation Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Nuvation Bio's ebitda for the twelve months ending Sep 30, 2026 was -$121.21M. For fiscal 2025 it was -$211.33M. The highest annual figure on record is -$43.45M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$211.33M | – |
| FY2024 | Dec 31, 2024 | -$591.94M | – |
| FY2023 | Dec 31, 2023 | -$99.60M | – |
| FY2022 | Dec 31, 2022 | -$119.54M | – |
| FY2021 | Dec 31, 2021 | -$93.13M | – |
| FY2020 | Dec 31, 2020 | -$43.45M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$41.63M | – |
| Q2 FY2026 | Jun 30, 2026 | -$50.50M | – |
| Q1 FY2026 | Mar 31, 2026 | $4.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$33.50M | – |
| Q3 FY2025 | Sep 30, 2025 | -$55.90M | – |
| Q2 FY2025 | Jun 30, 2025 | -$63.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$58.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$53.72M | – |
| Q3 FY2024 | Sep 30, 2024 | -$47.94M | – |
| Q2 FY2024 | Jun 30, 2024 | -$470.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.14M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.78M | – |
| Q3 FY2023 | Sep 30, 2023 | -$26.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.08M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.47M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.29M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -$37.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.57M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.39M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.45M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.74M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.52M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.99M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.20M | – |
See a number that looks wrong?